Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
New tuberculosis vaccines are urgently needed to curtail the current epidemic. MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as well as interactions with other routine vaccines administered in infancy, we randomized health...
Main Authors: | Ota, M, Odutola, A, Owiafe, P, Donkor, S, Owolabi, O, Brittain, N, Williams, N, Rowland-Jones, S, Hill, A, Adegbola, R, McShane, H |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2011
|
Similar Items
-
Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
by: Ota, M, et al.
Published: (2011) -
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
by: Odutola, A, et al.
Published: (2012) -
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
by: Odutola, A, et al.
Published: (2012) -
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Brookes, R, et al.
Published: (2008) -
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Roger H Brookes, et al.
Published: (2008-08-01)